

TRAIN - Key note lecture

Thursday May 4th, 4:30 pm
TWINCORE seminarroom 003

Innovative checkpoint inhibitors in cancer therapy: new career options in the pharmaceutical industry for academic employees



Dr. Engin Gürlevik
Manager für Medizin und Wissenschaft
Onkologie, Medical Affairs
MSD SHARP & DOHME GMBH

Host: Christiane Bock von Wülffingen, MHH / Prof. Ulrich Kalinke, TWINCORE

Who is Engin Gürlevik?

Engin Gürlevik studied biochemistry at Gottfried Wilhelm Leibniz Universität of Hannover from 1999 to 2005. Afterwards, he started his PhD thesis at Hannover Medical School on tumor-selective oncolytic adenoviruses. From 2009 to 2015, he continued his career as researcher and principal investigator at Hannover Medical School to establish new models for liver and pancreatic cancers, and to evaluate immunotherapeutic approaches in adjuvant and neoadjuvant settings. In 2015, he joined to MSD Sharp & Dohme as Medical Science Liaison to develop and represent the medical affairs immunoncology organization to the medical/scientific community.